Cite
HARVARD Citation
Ly, S. et al. (2021). Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. Journal for immunotherapy of cancer. 9 (3), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ly, S. et al. (2021). Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. Journal for immunotherapy of cancer. 9 (3), p. . [Online].